What this is
- How it works
- How it works isn't classified yet
- Tested for
- Early Alzheimer's Disease
- Main trialPhase 2
- “This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.”In the company’s words, NCT05531656 on ClinicalTrials.gov
- Other names
- zervimesine
Other drugs for Early Alzheimer's Disease
- Xanomeline/trospium chlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up1
- 31 May 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 31 May 2027 | A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease | |
| Phase 2Completed | 26 Apr 2023 | Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG | |
| Phase 2Completed | 29 May 2024 | A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. | |
| Phase 2Completed | 25 Nov 2024 | Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies | |
| Phase 2Terminated | 4 Mar 2025 | Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD). | |
| Phase 1/2Completed | 16 Oct 2020 | Effect of CT1812 Treatment on Brain Synaptic Density | |
| Phase 1Completed | 6 Feb 2019 | Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease | |
| Phase 1Completed | 17 Jan 2022 | Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects | |
| Phase 1Completed | 1 Jun 2022 | Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026